• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吗啡的 PBPK 模型,纳入了肝内 OCT1 和 UGT2B7 蛋白的发育变化,以解释新生儿和小婴儿清除率的变异性。

PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.

机构信息

Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):464-473. doi: 10.1002/psp4.12306. Epub 2018 Jun 19.

DOI:10.1002/psp4.12306
PMID:29920988
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6063742/
Abstract

Morphine has large pharmacokinetic variability, which is further complicated by developmental changes in neonates and small infants. The impacts of organic cation transporter 1 (OCT1) genotype and changes in blood-flow on morphine clearance (CL) were previously demonstrated in children, whereas changes in UDP-glucuronosyltransferase 2B7 (UGT2B7) activity showed a small effect. This study, targeting neonates and small infants, was designed to assess the influence of developmental changes in OCT1 and UGT2B7 protein expression and modified blood-flow on morphine CL using physiologically based pharmacokinetic (PBPK) modeling. The implementation of these three age-dependent factors into the pediatric system platform resulted in reasonable prediction for an age-dependent increase in morphine CL in these populations. Sensitivity of morphine CL to changes in cardiac output increased with age up to 3 years, whereas sensitivity to changes in UGT2B7 activity decreased. This study suggests that morphine exhibits age-dependent extraction, likely due to the developmental increase in OCT1 and UGT2B7 protein expression/activity and hepatic blood-flow.

摘要

吗啡具有较大的药代动力学变异性,新生儿和小婴儿的发育变化进一步使其复杂化。先前在儿童中已经证明了有机阳离子转运蛋白 1(OCT1)基因型和血流变化对吗啡清除率(CL)的影响,而 UDP-葡萄糖醛酸基转移酶 2B7(UGT2B7)活性的变化则显示出较小的影响。本研究针对新生儿和小婴儿,旨在使用基于生理学的药代动力学(PBPK)模型评估 OCT1 和 UGT2B7 蛋白表达和改良血流的发育变化对吗啡 CL 的影响。将这三个年龄相关因素纳入儿科系统平台中,可合理预测这些人群中吗啡 CL 的年龄依赖性增加。对心输出量变化的敏感性随着年龄的增长而增加,直至 3 岁,而对 UGT2B7 活性变化的敏感性则降低。本研究表明,吗啡表现出年龄依赖性提取,可能是由于 OCT1 和 UGT2B7 蛋白表达/活性和肝血流量的发育增加所致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/d1587972def0/PSP4-7-464-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/d07182c40440/PSP4-7-464-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/e635f26132bf/PSP4-7-464-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/1fc39b061ff4/PSP4-7-464-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/c2d93b5a7555/PSP4-7-464-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/15fab8e775c1/PSP4-7-464-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/d1587972def0/PSP4-7-464-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/d07182c40440/PSP4-7-464-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/e635f26132bf/PSP4-7-464-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/1fc39b061ff4/PSP4-7-464-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/c2d93b5a7555/PSP4-7-464-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/15fab8e775c1/PSP4-7-464-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded3/6063742/d1587972def0/PSP4-7-464-g006.jpg

相似文献

1
PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.吗啡的 PBPK 模型,纳入了肝内 OCT1 和 UGT2B7 蛋白的发育变化,以解释新生儿和小婴儿清除率的变异性。
CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):464-473. doi: 10.1002/psp4.12306. Epub 2018 Jun 19.
2
Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter.通过整合OCT1转运体的生理药代动力学(PBPK)模型对吗啡清除率变异性的影响因素进行表征。
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):110-119. doi: 10.1002/psp4.12144. Epub 2016 Dec 9.
3
Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study.OCT1 发育和遗传变异对危重新生儿吗啡处置的影响:来自 PBPK 模型和临床研究的经验教训。
Clin Pharmacol Ther. 2019 Mar;105(3):761-768. doi: 10.1002/cpt.1249. Epub 2018 Nov 8.
4
Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics.OCT1、ABCB1和UGT2B7基因变异与吗啡药代动力学之间缺乏遗传关联。
Eur J Pharm Sci. 2017 Mar 1;99:337-342. doi: 10.1016/j.ejps.2016.12.039. Epub 2017 Jan 4.
5
Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients.MRP3 基因与肝内表达对新生儿和儿科患者吗啡处置的影响。
J Clin Pharmacol. 2020 Aug;60(8):992-998. doi: 10.1002/jcph.1592. Epub 2020 Feb 24.
6
Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children.从新生儿到儿童肝脏有机阳离子转运体OCT1蛋白表达的发育变化
Drug Metab Dispos. 2017 Jan;45(1):23-26. doi: 10.1124/dmd.116.072256. Epub 2016 Oct 25.
7
Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver.年龄和基因型依赖性变化对人肝内 6 种主要尿苷二磷酸葡萄糖醛酸基转移酶的蛋白丰度和活性的影响。
Clin Pharmacol Ther. 2019 Jan;105(1):131-141. doi: 10.1002/cpt.1109. Epub 2018 Jul 12.
8
Pharmacogenomics and Morphine.药物基因组学与吗啡。
J Clin Pharmacol. 2021 Sep;61(9):1149-1155. doi: 10.1002/jcph.1873. Epub 2021 Jun 16.
9
Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4.细胞色素P450对尿苷二磷酸葡萄糖醛酸基转移酶功能的调节:细胞色素P450 3A4改变尿苷二磷酸葡萄糖醛酸基转移酶2B7催化的吗啡葡萄糖醛酸化的证据。
Mol Pharmacol. 2005 Mar;67(3):665-72. doi: 10.1124/mol.104.007641. Epub 2004 Dec 20.
10
UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.UGT2B7启动子变异体-840G>A导致镰状细胞病患者吗啡肝脏清除率的变异性。
Am J Hematol. 2008 Mar;83(3):200-2. doi: 10.1002/ajh.21051.

引用本文的文献

1
Review of Precision Medicine and Diagnosis of Neonatal Illness.精准医学与新生儿疾病诊断综述
Diagnostics (Basel). 2025 Feb 16;15(4):478. doi: 10.3390/diagnostics15040478.
2
The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation.利用定量临床药理学方法支持莫昔克丁在哺乳期的给药建议。
PLoS Negl Trop Dis. 2024 Aug 5;18(8):e0012351. doi: 10.1371/journal.pntd.0012351. eCollection 2024 Aug.
3
Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny.

本文引用的文献

1
The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.以吗啡为例说明基于生理的药代动力学模型在法医学中的可行性。
Int J Legal Med. 2018 Mar;132(2):415-424. doi: 10.1007/s00414-017-1754-8. Epub 2017 Dec 1.
2
Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter.通过整合OCT1转运体的生理药代动力学(PBPK)模型对吗啡清除率变异性的影响因素进行表征。
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):110-119. doi: 10.1002/psp4.12144. Epub 2016 Dec 9.
3
Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children.
结合咪达唑仑生物利用度数据和基于生理学的药代动力学模型研究肠道 CYP3A4 个体发育。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1570-1581. doi: 10.1002/psp4.13192. Epub 2024 Jun 26.
4
Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes.基于生理的药代动力学建模以预测不同CYP2D6表型中可待因的药代动力学。
Front Pharmacol. 2024 May 2;15:1342515. doi: 10.3389/fphar.2024.1342515. eCollection 2024.
5
Membrane transporters in drug development and as determinants of precision medicine.药物开发中的膜转运体和精准医学的决定因素。
Nat Rev Drug Discov. 2024 Apr;23(4):255-280. doi: 10.1038/s41573-023-00877-1. Epub 2024 Jan 24.
6
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives.新生儿基于生理学的药代动力学建模:现状与未来展望。
Pharmaceutics. 2023 Dec 12;15(12):2765. doi: 10.3390/pharmaceutics15122765.
7
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.新生儿群体中基于生理的药代动力学建模——当前进展、挑战与机遇
Pharmaceutics. 2023 Nov 3;15(11):2579. doi: 10.3390/pharmaceutics15112579.
8
An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science.法医学中基于生理学的药代动力学模型概述。
Toxics. 2023 Jan 28;11(2):126. doi: 10.3390/toxics11020126.
9
Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.定量蛋白质组学在转化吸收、分布、代谢和排泄及精准医学中的应用。
Pharmacol Rev. 2022 Jul;74(3):769-796. doi: 10.1124/pharmrev.121.000449.
10
Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.通过新型 PBPK 模型预测口服吸入药物的区域性呼吸组织和全身浓度。
Drug Metab Dispos. 2022 May;50(5):519-528. doi: 10.1124/dmd.121.000789. Epub 2022 Mar 4.
从新生儿到儿童肝脏有机阳离子转运体OCT1蛋白表达的发育变化
Drug Metab Dispos. 2017 Jan;45(1):23-26. doi: 10.1124/dmd.116.072256. Epub 2016 Oct 25.
4
Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.高加索人群肝脏转运体丰度的荟萃分析
Drug Metab Dispos. 2016 Oct;44(10):1550-61. doi: 10.1124/dmd.116.071183. Epub 2016 Aug 4.
5
Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.通过液相色谱-串联质谱蛋白质组学定量分析肝脏药物转运体的个体发生。
Clin Pharmacol Ther. 2016 Oct;100(4):362-70. doi: 10.1002/cpt.409. Epub 2016 Aug 13.
6
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.通过纳入器官血流的病理生理变化,采用基于生理的药代动力学方法预测卡维地洛在成人和儿童慢性心力衰竭患者中的立体选择性处置。
Drug Metab Dispos. 2016 Jul;44(7):1103-15. doi: 10.1124/dmd.115.068858. Epub 2016 Apr 11.
7
Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio.在将药物划分为高肝提取率与低肝提取率时考虑年龄差异。
Drug Metab Dispos. 2016 Jul;44(7):1099-102. doi: 10.1124/dmd.115.067595. Epub 2016 Feb 10.
8
Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.儿科药物治疗中的建模与模拟:药物代谢动力学在确定儿童正确剂量中的应用。
Clin Pharmacol Ther. 2015 Sep;98(3):298-308. doi: 10.1002/cpt.169. Epub 2015 Jul 20.
9
Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs.美国新生儿重症监护病房中新生儿戒断综合征的发病率不断上升。
N Engl J Med. 2015 May 28;372(22):2118-26. doi: 10.1056/NEJMsa1500439. Epub 2015 Apr 26.
10
Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.虚拟儿科药代动力学试验中个体药物非依赖性系统参数的变化:将时变生理学引入儿科 PBPK 模型。
AAPS J. 2014 May;16(3):568-76. doi: 10.1208/s12248-014-9592-9. Epub 2014 Apr 4.